Drug companies have hired auditors to perform compliance reviews mandated in government settlements over alleged civil violations.
Abbott Laboratories sought a way out of its $5.8 billion deal to acquire Alere Inc. in the wake of a bribery probe into that company’s sales practices in Africa, Asia and Latin America, Bloomberg reported.
Novartis opened a new $1 billion research facility on the outskirts of Shanghai, China. The facility is the company’s third major research center.
GlaxoSmithKline is on track to file its three-in-one inhaled lung drug for U.S. approval by the end of 2016 rather than during first-half 2018 as initially planned.
AstraZeneca has sold the European and Latin American rights to its new gout drug Zurampic to private German drugmaker Gruenenthal for up to $230 million, following a similar disposal of U.S. rights to the medicine.
Efforts by Novartis to defend its blockbuster cancer drug Afinitor against competitors got a boost from European regulators, who approved it for use on certain types of advanced gastrointestinal and lung neuroendocrine tumors.
Company continues to expand and disrupt the industry as Agency of the Future TORONTO, ON – June 1, 2016 – Start spreading the news – Klick Health today announced it is opening an office in New York as it continues to build one of the best talent rosters in the healthcare and pharma marketing […]
U.S. health officials recommended cutting the amount of salt added to foods to help Americans reduce their sodium consumption by about a third.
One company’s loss is another company’s gain. That’s certainly the case when looking at California-based Ionis Pharmaceuticals and Massachusetts-based Alnylam.
StemCells Inc. announced it will “wind down operations” following disappointing results of a Phase II spinal cord injury therapy study.
San Rafael, California-based BioMarin Pharmaceutical announced that it is abandoning its Kyndrisa (drisapersen) program for Duchenne muscular dystrophy (DMD).
Activist investor Carl Icahn posted on his website that he had acquired a “large position” in Dublin-based Allergan Plc. This statement had many investors and analysts raising their eyebrows.
New hepatitis C drugs that can cure the liver-destroying disease are revolutionizing treatment but their high price is a huge burden in some countries, particularly in central and eastern Europe, according to a new study.